Search research articles
Contact Us
Filters
Showing results (41-50 of 68) with videos related to
Page
of 7
Sort By:
The Journal of Pharmacology and Experimental Therapeutics
|
March 25, 2022
Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment-Related Early Diastolic Dysfunction
Giorgio Minotti, Emanuela Salvatorelli, Giorgio Reggiardo, et al.
Chemotherapy
|
January 16, 2018
Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy
Pierantonio Menna, Emanuela Salvatorelli, Alessia Mattei, et al.
Autoimmunity Reviews
|
May 5, 2011
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues
Fabio Cacciapaglia, Luca Navarini, Pierantonio Menna, et al.
Expert Opinion on Drug Safety
|
June 4, 2011
Anthracycline cardiotoxicity
Pierantonio Menna, Odalys Gonzalez Paz, Massimo Chello, et al.
Chemical Research in Toxicology
|
September 17, 2002
Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines
Pierantonio Menna, Emanuela Salvatorelli, Rossella Giampietro, et al.
Biochimica Et Biophysica Acta
|
January 18, 2015
The concomitant management of cancer therapy and cardiac therapy
Emanuela Salvatorelli, Pierantonio Menna, Emilia Cantalupo, et al.
Seminars in Oncology
|
November 27, 2019
Cardio-oncology in clinical studies and real life
Susan F Dent, Thomas M Suter, Teresa López-Fernández, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 15, 2006
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies
Emanuela Salvatorelli, Pierantonio Menna, Sabrina Cascegna, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 30, 2012
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients
Emanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
Chemotherapy
|
March 7, 2021
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life
Pierantonio Menna, Emanuela Salvatorelli, Maria Ilaria Del Principe, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 68) with videos related to
Sort By:
Page
of 7
The Journal of Pharmacology and Experimental Therapeutics
|
March 25, 2022
Cardiac Anthracycline Accumulation and B-Type Natriuretic Peptide to Define Risk and Predictors of Cancer Treatment-Related Early Diastolic Dysfunction
Giorgio Minotti, Emanuela Salvatorelli, Giorgio Reggiardo, et al.
Chemotherapy
|
January 16, 2018
Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy
Pierantonio Menna, Emanuela Salvatorelli, Alessia Mattei, et al.
Autoimmunity Reviews
|
May 5, 2011
Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues
Fabio Cacciapaglia, Luca Navarini, Pierantonio Menna, et al.
Expert Opinion on Drug Safety
|
June 4, 2011
Anthracycline cardiotoxicity
Pierantonio Menna, Odalys Gonzalez Paz, Massimo Chello, et al.
Chemical Research in Toxicology
|
September 17, 2002
Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines
Pierantonio Menna, Emanuela Salvatorelli, Rossella Giampietro, et al.
Biochimica Et Biophysica Acta
|
January 18, 2015
The concomitant management of cancer therapy and cardiac therapy
Emanuela Salvatorelli, Pierantonio Menna, Emilia Cantalupo, et al.
Seminars in Oncology
|
November 27, 2019
Cardio-oncology in clinical studies and real life
Susan F Dent, Thomas M Suter, Teresa López-Fernández, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 15, 2006
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies
Emanuela Salvatorelli, Pierantonio Menna, Sabrina Cascegna, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
November 30, 2012
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients
Emanuela Salvatorelli, Pierantonio Menna, Odalys Gonzalez Paz, et al.
Chemotherapy
|
March 7, 2021
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life
Pierantonio Menna, Emanuela Salvatorelli, Maria Ilaria Del Principe, et al.
Page
of 7